|
US20030091630A1
(en)
*
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
US20030152622A1
(en)
*
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
|
EP1492511B3
(fr)
|
2002-04-09 |
2012-05-02 |
Flamel Technologies |
Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
|
|
BRPI0406749A
(pt)
|
2003-01-13 |
2005-12-20 |
Dynogen Pharmaceuticals Inc |
Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica
|
|
WO2004066997A2
(en)
*
|
2003-01-30 |
2004-08-12 |
Lek Pharmaceuticals D.D. |
Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods
|
|
EP3045174A1
(en)
*
|
2003-01-31 |
2016-07-20 |
Daiichi Sankyo Company, Limited |
Medicine for prevention of and treatment for arteriosclerosis and hypertension
|
|
US20070196396A1
(en)
*
|
2004-02-11 |
2007-08-23 |
Rubicon Research Private Limited |
Controlled release pharmaceutical compositions with improved bioavailability
|
|
US7838552B2
(en)
*
|
2004-06-04 |
2010-11-23 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
|
KR20070074576A
(ko)
*
|
2004-10-29 |
2007-07-12 |
코와 가부시키가이샤 |
사구체 질환 치료제
|
|
FR2882260A1
(fr)
*
|
2005-02-21 |
2006-08-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
|
|
FR2884145A1
(fr)
*
|
2005-04-06 |
2006-10-13 |
Flamel Technologies Sa |
Forme pharmaceutique orale de losartan
|
|
US20090123536A1
(en)
*
|
2005-02-21 |
2009-05-14 |
Flamel Technologies, S.A. |
Oral Pharmaceutical Form of Losartan
|
|
CN101247832B
(zh)
*
|
2005-06-27 |
2011-12-28 |
第一三共株式会社 |
含有血管紧张素ⅱ受体拮抗剂和钙通道阻断剂的药物制剂
|
|
DE102005031577A1
(de)
|
2005-07-06 |
2007-01-11 |
Bayer Healthcare Ag |
Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
|
|
US20070021379A1
(en)
|
2005-07-11 |
2007-01-25 |
Pharmena North America Inc. |
Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities
|
|
TWI399223B
(zh)
*
|
2006-09-15 |
2013-06-21 |
Daiichi Sankyo Co Ltd |
奧美沙坦酯及氨氯地平之固體劑型
|
|
KR100888131B1
(ko)
*
|
2006-10-10 |
2009-03-11 |
한올제약주식회사 |
시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
|
|
WO2009084040A1
(en)
*
|
2007-12-28 |
2009-07-09 |
Rubicon Research Private Limited |
Once a day formulation of angiotensin receptor blockers
|
|
US8372432B2
(en)
|
2008-03-11 |
2013-02-12 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
|
AU2009223061B2
(en)
|
2008-03-11 |
2014-10-09 |
Depomed Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
|
US20110117194A1
(en)
|
2008-04-29 |
2011-05-19 |
Hanall Biopharma Co., Ltd. |
Pharmaceutical formulation containing angiotensin-ii receptor blocker
|
|
UY32126A
(es)
*
|
2008-09-25 |
2010-04-30 |
Takeda Pharmaceutical |
Composición farmacéutica sólida
|
|
DE102008059206A1
(de)
|
2008-11-27 |
2010-06-10 |
Bayer Schering Pharma Aktiengesellschaft |
Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
|
|
AU2010245932B2
(en)
|
2009-05-05 |
2015-08-06 |
Board Of Regents, The University Of Texas System |
Novel formulations of volatile anesthetics and methods of use for reducing inflammation
|
|
US8597681B2
(en)
|
2009-12-22 |
2013-12-03 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
|
US9198861B2
(en)
|
2009-12-22 |
2015-12-01 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
|
EP2392318A1
(en)
|
2010-05-21 |
2011-12-07 |
Laboratorios Liconsa, S.A. |
A pharmaceutical controlled release composition of losartan
|
|
CN103347517B
(zh)
|
2010-08-11 |
2018-10-02 |
德雷克塞尔大学 |
治疗帕金森病中运动障碍的d3多巴胺受体激动剂
|
|
EP2648754A4
(en)
|
2010-12-07 |
2016-02-24 |
Philadelphia Health & Educatio |
METHOD OF INHIBITING CANCER METASTASES
|
|
US8476221B2
(en)
|
2011-03-18 |
2013-07-02 |
Halimed Pharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders
|
|
US8741885B1
(en)
|
2011-05-17 |
2014-06-03 |
Mallinckrodt Llc |
Gastric retentive extended release pharmaceutical compositions
|
|
US8658631B1
(en)
|
2011-05-17 |
2014-02-25 |
Mallinckrodt Llc |
Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
|
|
US8858963B1
(en)
|
2011-05-17 |
2014-10-14 |
Mallinckrodt Llc |
Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
|
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
|
KR101699822B1
(ko)
|
2011-12-21 |
2017-01-25 |
노비라 테라퓨틱스, 인코포레이티드 |
B형 간염의 항바이러스성 제제
|
|
MX2014013320A
(es)
|
2012-05-07 |
2015-08-10 |
Bayer Pharma AG |
Procedimiento de fabricacion de una forma de dosificacion farmaceutica que comprende nifedipina y candesartan cilexetilo.
|
|
AU2013292519B2
(en)
|
2012-07-19 |
2017-12-07 |
Drexel University |
Sigma receptor ligands for modulating cellular protein homeostasis
|
|
ES2689906T3
(es)
|
2012-08-09 |
2018-11-16 |
Dynamis Therapeutics, Inc. |
Meglumina para reducir los niveles altos de triglicéridos
|
|
EP2941233B1
(en)
|
2013-01-07 |
2020-10-07 |
The Trustees of the University of Pennsylvania |
Compositions and methods for treating cutaneous t cell lymphoma
|
|
CN105431144A
(zh)
|
2013-06-05 |
2016-03-23 |
思康脑侒股份有限公司 |
阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
|
|
EP3017054B1
(en)
|
2013-07-02 |
2019-11-13 |
EcoPlanet Environmental LLC |
Volatile organic compound formulations having antimicrobial activity
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
WO2015028972A1
(en)
|
2013-09-02 |
2015-03-05 |
Ranbaxy Laboratories Limited |
Pulsatile-release dosage form
|
|
US9908915B2
(en)
|
2013-11-26 |
2018-03-06 |
Yale University |
Cell-penetrating compositions and methods using same
|
|
JP6449293B2
(ja)
|
2013-12-06 |
2019-01-09 |
ジェネンテック， インコーポレイテッド |
セリン／トレオニンキナーゼ阻害剤
|
|
EP3079692A4
(en)
|
2013-12-09 |
2017-10-18 |
Thomas Jefferson University |
Novel methods of treating a neurodegenerative disease in a mammal in need thereof
|
|
US9982010B2
(en)
|
2014-04-07 |
2018-05-29 |
Women & Infants Hospital Of Rhode Island |
7-dehydrocholesterol derivatives and methods using same
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US10624917B2
(en)
|
2014-08-20 |
2020-04-21 |
Yale University |
Compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
|
|
WO2016182968A1
(en)
|
2015-05-08 |
2016-11-17 |
Brown University |
Novel syringolin analogues and methods of making and using same
|
|
EP3298140B1
(en)
|
2015-05-19 |
2024-04-24 |
Yale University |
Compositions for treating pathological calcification conditions, and methods using same
|
|
US10829440B2
(en)
|
2015-06-12 |
2020-11-10 |
Brown University |
Antibacterial compounds and methods of making and using same
|
|
WO2017003822A1
(en)
|
2015-06-30 |
2017-01-05 |
Galleon Pharmaceuticals, Inc. |
Novel breathing control modulating compounds, and methods of making and using same
|
|
JP2018521077A
(ja)
*
|
2015-07-29 |
2018-08-02 |
タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ |
糖尿病性腎症を治療するためのｐｄｅ４阻害剤
|
|
EP3368505B1
(en)
|
2015-10-28 |
2023-02-22 |
Yale University |
Quinoline amides and methods of using same
|
|
AU2016355715A1
(en)
|
2015-11-20 |
2018-05-31 |
Yale University |
Compositions for treating ectopic calcification disorders, and methods using same
|
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
|
EP3448369B1
(en)
|
2016-04-29 |
2025-06-25 |
The Regents of The University of Colorado, A Body Corporate |
Inhibition or degradation of hdac11 for treating obesity, hyperlipidemia, type ii diabetes, metabolic syndrome or insulin resistance, for promoting weight loss, and/or ameliorating or preventing weight gain
|
|
US20210330599A1
(en)
|
2016-08-01 |
2021-10-28 |
University Of Rochester |
Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
|
|
US11390859B2
(en)
|
2016-08-05 |
2022-07-19 |
Yale University |
Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
|
|
WO2018045229A1
(en)
|
2016-09-01 |
2018-03-08 |
Mebias Discovery Llc |
Substituted ureas and methods of making and using same
|
|
CN110114071B
(zh)
|
2016-11-07 |
2023-07-04 |
爱彼特生物制药公司 |
含有取代的吡啶酮的三环化合物以及使用其的方法
|
|
EP3571196B1
(en)
|
2017-01-19 |
2023-01-04 |
Temple University Of The Commonwealth System Of Higher Education |
Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use
|
|
MA49014A
(fr)
|
2017-03-21 |
2020-02-05 |
Arbutus Biopharma Corp |
Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
|
|
IL270070B2
(en)
|
2017-04-17 |
2023-09-01 |
Univ Yale |
Compounds, compositions and methods for treating or preventing acute lung injury
|
|
EP3659307A4
(en)
|
2017-07-28 |
2021-09-22 |
Yale University |
ANTI-CANCER PRODUCTS AND METHOD FOR MANUFACTURING AND USING THEREOF
|
|
KR20200072478A
(ko)
|
2017-09-08 |
2020-06-22 |
더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 |
Her-구동된 약물-내성암의 치료 또는 예방을 위한 화합물, 조성물 및 방법
|
|
US20200323895A1
(en)
|
2017-11-27 |
2020-10-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Compounds, Compositions, and Methods for Treating And/Or Preventing Periodontal Disease
|
|
IL275312B2
(en)
|
2017-12-18 |
2024-09-01 |
Tris Pharma Inc |
Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
|
US11337919B2
(en)
|
2017-12-18 |
2022-05-24 |
Tris Pharma, Inc. |
Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release
|
|
US11337920B2
(en)
|
2017-12-18 |
2022-05-24 |
Tris Pharma, Inc. |
Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
|
|
WO2019125184A1
(en)
|
2017-12-19 |
2019-06-27 |
Auckland Uniservices Limited |
Use of biomarker in cancer therapy
|
|
WO2019147753A1
(en)
|
2018-01-24 |
2019-08-01 |
The Rockefeller University |
Antibacterial compounds, compositions thereof, and methods using same
|
|
BR112020024048A2
(pt)
|
2018-05-25 |
2021-02-17 |
Temple University-Of The Commonwealth System Of Higher Education |
composição, e, métodos para descolonizar um organismo microbiano, para destruir ou interromper ou inibir ou reduzir a formação de biofilme de um organismo microbiano e para tratar uma infecção microbiana em um indivíduo.
|
|
WO2019231739A1
(en)
|
2018-05-29 |
2019-12-05 |
Cersci Therapeutics, Inc. |
Compounds for pain treatment, compositions comprising same, and methods of using same
|
|
TWI826492B
(zh)
|
2018-07-27 |
2023-12-21 |
加拿大商愛彼特生物製藥公司 |
經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
|
|
AU2019321654B8
(en)
|
2018-08-17 |
2025-08-07 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of acute lung injury
|
|
WO2020074944A1
(en)
|
2018-10-11 |
2020-04-16 |
Sanifit Therapeutics S.A. |
Inositol phosphates for the treatment of ectopic calcification
|
|
US12458601B2
(en)
|
2018-10-19 |
2025-11-04 |
Temple University-Of The Commonwealth System Of Higher Education |
Tamper-resistant drug dosage forms and methods of making and use thereof
|
|
TWI827760B
(zh)
|
2018-12-12 |
2024-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
|
BR112021014897A2
(pt)
|
2019-01-30 |
2021-09-28 |
Sanifit Therapeutics, S.A. |
Composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
|
|
US20200246316A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
|
|
WO2020159588A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
|
|
WO2020227603A1
(en)
|
2019-05-09 |
2020-11-12 |
The Feinstein Institutes For Medical Research |
Hmgb1 antagonist
|
|
JP2022538767A
(ja)
|
2019-06-12 |
2022-09-06 |
ザ ウィスター インスティテュート |
アセチルＣｏＡシンテターゼ２（ＡＣＳＳ２）阻害剤およびそれを使用する方法
|
|
US11555010B2
(en)
|
2019-07-25 |
2023-01-17 |
Brown University |
Diamide antimicrobial agents
|
|
EP3818983A1
(en)
|
2019-11-11 |
2021-05-12 |
Sanifit Therapeutics S.A. |
Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
|
|
WO2021127456A1
(en)
|
2019-12-19 |
2021-06-24 |
Rain Therapeutics Inc. |
Methods of inhibiting epidermal growth factor receptor proteins
|
|
IL298853A
(en)
|
2020-06-09 |
2023-02-01 |
Inozyme Pharma Inc |
Soluble enpp1 or enpp3 proteins and uses thereof
|
|
EP4015494A1
(en)
|
2020-12-15 |
2022-06-22 |
Sanifit Therapeutics S.A. |
Processes for the preparation of soluble salts of inositol phosphates
|
|
EP4036097A1
(en)
|
2021-01-29 |
2022-08-03 |
Sanifit Therapeutics S.A. |
Ip4-4,6 substituted derivative compounds
|
|
IL318658A
(en)
|
2022-07-29 |
2025-03-01 |
Sanifit Therapeutics S A |
IP4-4,6-Substituted Derivative Compounds for Use in the Treatment, Inhibition of Progression, and Prevention of Ectopic Calcification
|
|
TW202412815A
(zh)
|
2022-07-29 |
2024-04-01 |
西班牙商薩尼菲特治療公司 |
Ip5經取代化合物
|
|
IL319372A
(en)
|
2022-09-06 |
2025-05-01 |
Hadasit Med Res Service |
Combinations involving psychedelic drugs for the treatment of chronic schizophrenia and other neuropsychiatric and neurological disorders
|
|
WO2025037248A1
(en)
|
2023-08-14 |
2025-02-20 |
Neurim Pharmaceuticals (1991) Ltd. |
Gal475 compositions and methods of use thereof
|
|
WO2025162971A1
(en)
|
2024-01-31 |
2025-08-07 |
Sanifit Therapeutics, S.A. |
Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
|
|
WO2025217096A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
|
|
WO2025217094A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof
|
|
WO2025217379A1
(en)
|
2024-04-10 |
2025-10-16 |
University Of Rochester |
Drug treatment for macular degeneration
|